FDA permits trial of Omeros drug for thrombotic microangiopathies

04/3/2014 | FDAnews

Omeros obtained the FDA's approval to initiate a midstage trial of its monoclonal antibody candidate OMS721 in patients with complement-mediated thrombotic microangiopathies. The trial, which will test the safety and efficacy of the drug, is scheduled to start this quarter.

View Full Article in:

FDAnews

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC